| pubmed-article:1280026 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0013080 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0018062 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0220908 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C0206015 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C1996904 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C1880497 | lld:lifeskim |
| pubmed-article:1280026 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:1280026 | pubmed:dateCreated | 1992-12-1 | lld:pubmed |
| pubmed-article:1280026 | pubmed:abstractText | To ascertain the value of maternal serum free beta-human choriogonadotropin subunit measurement in Down's syndrome screening and to compare its effectiveness when screening with a variety of biochemical markers, we have evaluated maternal serum free beta-human choriogonadotropin, total human choriogonadotropin, alpha-fetoprotein and unconjugated oestriol in a large multicentre study of over 2800 unaffected cases and 90 affected cases, the largest collection of Down's cases ever reported. Of all the markers identified to date, free beta-human choriogonadotropin is the marker of choice for use in Down's syndrome screening. When used in early gestation (14-16 weeks) in combination with alpha-fetoprotein and maternal age, it will allow the detection of 77% of Down's cases. A side-by-side comparison with the performance of total human choriogonadotropin shows the superior detection efficiency of free beta-human choriogonadotropin. Unconjugated oestriol adds nothing further to the detection rate compared with the use of alpha-fetoprotein and free beta-human choriogonadotropin alone, and its use results in a 1% increase in false positive rate. We conclude that unconjugated oestriol has no value in Down's screening. The superior detection rate obtained using free beta-human choriogonadotropin is a result of superior detection of Down's cases in women under 30 years old, where the free beta-human choriogonadotropin combination detects 100% more cases than does the total human choriogonadotropin combination. | lld:pubmed |
| pubmed-article:1280026 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1280026 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1280026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1280026 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1280026 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:1280026 | pubmed:issn | 0004-5632 | lld:pubmed |
| pubmed-article:1280026 | pubmed:author | pubmed-author:WardA MAM | lld:pubmed |
| pubmed-article:1280026 | pubmed:author | pubmed-author:SpencerKK | lld:pubmed |
| pubmed-article:1280026 | pubmed:author | pubmed-author:CoombesE JEJ | lld:pubmed |
| pubmed-article:1280026 | pubmed:author | pubmed-author:MallardA SAS | lld:pubmed |
| pubmed-article:1280026 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1280026 | pubmed:volume | 29 ( Pt 5) | lld:pubmed |
| pubmed-article:1280026 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1280026 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1280026 | pubmed:pagination | 506-18 | lld:pubmed |
| pubmed-article:1280026 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:meshHeading | pubmed-meshheading:1280026-... | lld:pubmed |
| pubmed-article:1280026 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1280026 | pubmed:articleTitle | Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. | lld:pubmed |
| pubmed-article:1280026 | pubmed:affiliation | Clinical Biochemistry Department, Oldchurch Hospital, Romford, Essex, UK. | lld:pubmed |
| pubmed-article:1280026 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1280026 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1280026 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1280026 | lld:pubmed |
